Table 2 Characteristics of patients treated with talimogene laherparepvec in OPTiM by complete response and partial response (per investigator assessment)a
Characteristic | Complete response (n = 50) | Partial response (n = 43) |
|---|---|---|
Median (IQR) age, years | 70 (60–78) | 63 (53–77) |
Female | 20 (40) | 21 (49) |
ECOG performance status = 0 | 42 (84) | 31 (72) |
AJCC stage | ||
IIIB/C | 31 (62) | 15 (35) |
IVM1a | 15 (30) | 14 (33) |
IIIB–IVM1a | 46 (92) | 29 (67) |
IVM1b | 2 (4) | 7 (16) |
IVM1c | 2 (4) | 7 (16) |
In-transit or distant skin metastases | ||
IIIB–IVM1a | 42 (84) | 20 (47) |
IIIB–IVM1c | 44 (88) | 26 (60) |
Elevated LDH (>ULN) | 0 | 0 |
Line of treatment | ||
1st | 33 (66) | 27 (63) |
≥ 2nd | 17 (34) | 16 (37) |
Median baseline tumor burden (range), cm2 | 4.6 (0.3–38.3) | 10.9 (0.6–280.6) |
BRAF status | ||
Mutation | 5 (10) | 9 (21) |
Wild type | 5 (10) | 9 (21) |
Unknown/missing | 40 (80) | 25 (58) |
HSV-1 seropositive at baseline | 32 (64) | 28 (65) |